Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center Identifier:
First received: September 13, 2001
Last updated: October 28, 2015
Last verified: July 2012

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.

PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Condition Intervention Phase
Lung Cancer
Malignant Mesothelioma
Metastatic Cancer
Thymoma and Thymic Carcinoma
Procedure: radiofrequency ablation
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Radiofrequency Ablation of Pulmonary Malignancy

Resource links provided by NLM:

Further study details as provided by Jonsson Comprehensive Cancer Center:

Enrollment: 30
Study Start Date: May 2000
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies.
  • Determine the efficacy of this treatment, in terms of local control, in these patients.
  • Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients.

OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours.

Patients are followed at 1, 3, 6, and 12 months.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of a primary or secondary intrathoracic malignancy

    • Any cell type or origin
    • Involving the intrapulmonary, mediastinal, or pleural/chest wall
    • Inoperable primary or metastatic cancer to the lung
  • Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy)
  • Single or multiple lesions that are non-contiguous with vital structures or organs such as:
  • Trachea
  • Heart
  • Aorta
  • Great vessels
  • Esophagus
  • Less than 5 cm in largest dimension
  • Accessible via percutaneous transthoracic route
  • Hepatic:

    • Coagulation profile normal
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00024076

United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Study Chair: Robert D. Suh, MD Jonsson Comprehensive Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT00024076     History of Changes
Other Study ID Numbers: CDR0000068889, P30CA016042, UCLA-9908024, NCI-G01-2011
Study First Received: September 13, 2001
Last Updated: October 28, 2015
Health Authority: United States: Federal Government

Keywords provided by Jonsson Comprehensive Cancer Center:
recurrent non-small cell lung cancer
recurrent small cell lung cancer
recurrent malignant mesothelioma
recurrent thymoma and thymic carcinoma
stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
pulmonary carcinoid tumor
lung metastases

Additional relevant MeSH terms:
Lung Neoplasms
Neoplasm Metastasis
Lung Diseases
Lymphatic Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Complex and Mixed
Neoplasms, Glandular and Epithelial
Neoplasms, Mesothelial
Neoplastic Processes
Pathologic Processes
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Thymus Neoplasms processed this record on November 25, 2015